Clinical trials: Head and Neck Squamous Cell Cancer
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Phase 1b open-label study to evaluate the safety of selected TIL (TBio-4101) delivered after lymphodepleting chemotherapy and followed by intravenous (IV) bolus aldesleukin (IL-2) and pembrolizumab for patients with advanced…
- Trial name
- NCT06236425
- Testing
- TBio-4101, Pembrolizumab, Platinum based chemotherapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Esophageal Squamous Cell Carcinoma
Precisely Estimation of the Prognostic Value of Lymph Node in ESCC
Data were collected on a large multi-institution dataset consisting of ESCC patients who underwent surgery between January 2003 and December 2013 at ten institutions in the People's Republic of China.
- Trial name
- NCT04764240
- Testing
- R0 resection with lymphadenectomy
- Volunteers
- 3,700 people
- Sponsor
- Shanghai Cancer Hospital, China
Locally Advanced Esophageal Squamous Cell Carcinoma
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
Although definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer, elderly patients tolerate intravenous concurrent CRT less well with age and comorbidities.
- Trial name
- EC-CRT-007 (NCT06187597)
- Testing
- S-1, Toripalimab, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this study is to investigate the impact of combining Nimotuzumab with analgesic agents on pain management outcomes, as well as the effectiveness and safety profile of this therapeutic combination in the…
- Trial name
- NCT06879691
- Testing
- Nimotuzumab, cis-platinum, IMRT combine with cisplatin concurrent chemotherapy
- Where
- China
- Volunteers
- 171 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
This phase II trial investigates the effect of NBTXR3, radiation therapy, and pembrolizumab in treating patients with head and neck squamous cancer that has come back (recurrent) or has spread to other places in the body…
- Trial name
- NCT04862455
- Testing
- Hafnium Oxide-containing Nanoparticles NBTXR3, Hypofractionated Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
A Window of Opportunity Study of Black Raspberry for Patients With HNSCC
The purpose of this phase 0 Window of Opportunity study is to have subjects with Head and Neck Squamous Cell Carcinoma (HNSCC) receive same dosage of Black Raspberry Extract between their cancer diagnosis and standard treatment…
- Trial name
- NCT06086925
- Testing
- Black Raspberry
- Sponsor
- Mitchell Machtay
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard…
- Conditions
- Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC
- Trial name
- NCT05859074
- Testing
- MQ719, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms, Head and Neck
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic…
- Trial name
- NCT06062420
- Testing
- Dostarlimab, Belrestotug, Nelistotug
- Where
- 108 sites in United States, Argentina and 18 more
- Volunteers
- 316 people
- Sponsor
- GlaxoSmithKline
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Trial name
- NCT00023959
- Testing
- hydroxyurea, fluorouracil, bevacizumab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
This clinical trial studies how well intensity modulated proton therapy (IMPT) or intensity modulated X-ray (radiation) therapy (IMRT) works after surgery in treating patients with head and neck cancer.
- Conditions
- Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary, Hypopharyngeal Carcinoma, Laryngeal Carcinoma
- Trial name
- NCT05075980
- Testing
- Cisplatin, Intensity-Modulated Proton Therapy, Quality-of-Life Assessment
- Where
- 9 sites in United States
- Volunteers
- 174 people
- Sponsor
- Mayo Clinic
Head and Neck Squamous Cell Carcinoma
Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer
The investigators designed a prospective randomized double-blind trial to determine if the oral immunomodulating formula could improve the disease-free survival rate in high-risk locally-advanced head and neck Squamous Cell…
- Trial name
- SIMPA01 (NCT04001543)
- Testing
- Immunomodulating oral supplementation, Sip feed control
- Where
- 2 sites in France
- Volunteers
- 27 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Head and Neck Cancer
Gene Expression Profiles in Predicting Survival of Patients With Head and Neck Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897052
- Testing
- microarray analysis, laboratory biomarker analysis
- Volunteers
- 29 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Esophageal Cancer
Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)
The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens (STF-II) for locally advanced, recurrent, or metastatic esophageal squamous…
- Trial name
- NCT01267578
- Testing
- vaccination
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- University of Yamanashi
Head and Neck Squamous Cell Carcinoma
Dose Escalation Using Hypoxia-adjusted Radiotherapy
DE-HyART is a phase II clinical trial aimed at understanding the effects of escalating radiation doses to hypoxic sub-volumes inherent to squamous cell head and neck cancer.
- Trial name
- DE-HyART (NCT06087614)
- Testing
- DE-HyART, Standard Arm, Cisplatin injection
- Where
- India
- Volunteers
- 124 people
- Sponsor
- Rajiv Gandhi Cancer Institute & Research Center, India
Head and Neck Squamous Cell Carcinoma, Radiotherapy
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.
Hypoxic modification of radiotherapy with nimorazole has previously been shown to increase radiosensitivity in hypoxic head and neck squamous cell carcinomas (HNSCC).
- Conditions
- Head and Neck Squamous Cell Carcinoma, Radiotherapy, Hypoxic Modification, Hypoxia
- Trial name
- DAHANCA30 (NCT02661152)
- Testing
- Nimorazole
- Where
- Denmark
- Volunteers
- 1,252 people
- Sponsor
- Danish Head and Neck Cancer Group
Non Small Cell Lung Cancer, Cancer of the Head and Neck
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
The purpose of this study is to provide ZD1839 for those patients with locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III or IV) or recurrent and/or metastatic squamous cell head and neck cancer…
- Trial name
- NCT00684385
- Testing
- ZD1839
- Where
- 34 sites in Germany, Hungary and 2 more
- Sponsor
- AstraZeneca
Head and Neck Cancer
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer
The purpose of this study is to find out whether adding ZD1839 to standard treatment (Cisplatin and Radiation Therapy) of unresectable head and neck cancers is better than cisplatin and radiation alone.
- Trial name
- NCT00195078
- Testing
- ZD1839 (IRESSA), Cisplatin, Radiation Therapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Weill Medical College of Cornell University
Advanced or Metastatic Solid Tumors, Lung Cancer
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03665285
- Testing
- NC318
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- NextCure, Inc.
Head and Neck Cancer
S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006248
- Testing
- cisplatin, fluorouracil, paclitaxel
- Where
- 95 sites in United States
- Volunteers
- 78 people
- Sponsor
- SWOG Cancer Research Network
Esophageal Squamous Cell Carcinoma
Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes
The goal of this clinical trial is to learn whether postoperative immunotherapy combined with anlotinib can help prevent or delay cancer recurrence in adults aged 18 to 75 years with locally advanced esophageal squamous cell…
- Trial name
- NCT07830355
- Testing
- Anlotinib, Anti-PD-1 Monoclonal Antibody
- Volunteers
- 75 people
- Sponsor
- Shanghai Chest Hospital